We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Building upon a successful end-of-Phase 2 meeting, received FDA βStudy May Proceedβ letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced...
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (βTempestβ or the βCompanyβ), a clinical-stage biotechnology company developing first-in-classi...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -13.2075471698 | 1.06 | 1.16 | 0.92 | 2511983 | 1.04268116 | CS |
4 | -0.21 | -18.5840707965 | 1.13 | 1.21 | 0.8637 | 3197160 | 1.04135621 | CS |
12 | -0.57 | -38.255033557 | 1.49 | 1.59 | 0.8637 | 3225222 | 1.10335733 | CS |
26 | -2.49 | -73.0205278592 | 3.41 | 3.6499 | 0.8637 | 2931626 | 1.39914884 | CS |
52 | -2.24 | -70.8860759494 | 3.16 | 6 | 0.8637 | 1995043 | 2.08656267 | CS |
156 | -10.46 | -91.9156414763 | 11.38 | 11.98 | 0.17 | 1598801 | 4.3693515 | CS |
260 | -12.89 | -93.3381607531 | 13.81 | 41 | 0.17 | 1464815 | 4.89075057 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions